Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) Net Income towards Common Stockholders: 2019-2025

Historic Net Income towards Common Stockholders for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to -$38.5 million.

  • Legend Biotech's Net Income towards Common Stockholders fell 157.58% to -$38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.7 million, marking a year-over-year decrease of 130.38%. This contributed to the annual value of -$177.0 million for FY2024, which is 65.84% up from last year.
  • Per Legend Biotech's latest filing, its Net Income towards Common Stockholders stood at -$38.5 million for Q3 2025, which was up 69.04% from -$124.2 million recorded in Q2 2025.
  • Legend Biotech's 5-year Net Income towards Common Stockholders high stood at $257.8 million for Q2 2022, and its period low was -$135.9 million during Q4 2022.
  • For the 3-year period, Legend Biotech's Net Income towards Common Stockholders averaged around $48.1 million, with its median value being $66.8 million (2024).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 35,570.18% in 2022, then soared by 447.18% in 2023.
  • Quarterly analysis of 5 years shows Legend Biotech's Net Income towards Common Stockholders stood at -$88.3 million in 2021, then tumbled by 53.82% to -$135.9 million in 2022, then skyrocketed by 99.89% to -$144,818 in 2023, then soared by 118.15% to $26,284 in 2024, then tumbled by 157.58% to -$38.5 million in 2025.
  • Its Net Income towards Common Stockholders was -$38.5 million in Q3 2025, compared to -$124.2 million in Q2 2025 and $100.9 million in Q1 2025.